THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 52 filers reported holding THESEUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $403,500 | +12254.6% | 150,000 | -57.1% | 0.02% | -86.1% |
| Q2 2023 | $3,266 | +5.1% | 350,000 | 0.0% | 0.15% | -1.3% |
| Q1 2023 | $3,108 | -99.8% | 350,000 | -15.7% | 0.15% | +40.4% |
| Q4 2022 | $2,066,700 | -60.1% | 415,000 | -53.5% | 0.11% | -62.5% |
| Q3 2022 | $5,174,000 | +4.9% | 892,057 | 0.0% | 0.29% | -6.7% |
| Q2 2022 | $4,933,000 | -52.0% | 892,057 | 0.0% | 0.31% | -41.0% |
| Q1 2022 | $10,285,000 | -9.1% | 892,057 | 0.0% | 0.53% | +20.5% |
| Q4 2021 | $11,311,000 | – | 892,057 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |